Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafluprost plus timolol vs timolol alone in open-angle glaucoma or ocular hypertension
2004-004974-94Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Feb 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing Tafluprost adjunctive to timolol with Placebo adjunctive to timolol (2 arms). Primary endpoints: Change from baseline in diurnal intraocular pressure at 2 weeks, Change from baseline in diurnal intraocular pressure at 4 weeks and 1 more. Started Feb 2005; status: completed.
02
Drugs
tafluprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2004-004974-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004974-94.